Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT ...
Predictors of response to neoadjuvant chemotherapy in estrogen receptor-positive breast cancer. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This abstract does not include a ...
Expert Rev Anticancer Ther. 2009;9(1):75-96. Based on the available data, FDG-PET alone appears to be of limited use in differentiating tumors of low malignant potential from benign tumors and ovarian ...
Dose-intensified ONC201 to exert anti-metastatic efficacy and to promote intra-tumoral recruitment of NK-cells in mice. This is an ASCO Meeting Abstract from the 2016 ASCO Annual Meeting I. This ...
Advances in Total-Body PET/CT Research. Journal of Biosciences and Medicines, 14, 274-282. doi: 10.4236/jbm.2026.141021 . PET ...
Fluorodeoxyglucose (FDG) has proven benefits as a positron emission tomography (PET) radiopharmaceutical in oncology. However, it has limitations in the assessment of certain tumours, above all (but ...
A shortage of radioactive tracer has left Saskatchewan’s only PET/CT scanner, used to diagnose serious health conditions, ...
For the first time, physicians can examine the systemic burden of inflammatory arthritis simultaneously across all joints and organ systems, using the high-sensitivity, high-resolution uEXPLORER total ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback